Bsf Enterprise Plc · LSE:BSFA
Bsf Enterprise — Investor Presentation (September 2023)
25 slides from Bsf Enterprise's investor presentation, September 2023
Slide 1: Unlocking the next generation of biotech solutions
Unlocking the next generation of biotech solutions. LON: BSFA (UK) | BSFAF: QBB (US) INVESTOR PRESENTATION September 2023 © 2023 BSF Enterprise PLC. All rights reserved.
Slide 2: Presentation Disclaimer
Presentation Disclaimer. The information contained in these slides and communicated orally to you, including the speech(es) of the presenter(s) and any materials distributed at or in connection therewith (together, the “Presentation”) is confidential. By reading the information contained in this Pre
Slide 3: Presentation Disclaimer (continued)
Presentation Disclaimer (continued). The Presentation has not been approved by the FCA and does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or
Slide 4: Presentation Team
Presentation Team. § Joined BSF as Non-Executive Director § Managing Director of BSF Enterprise after practising law for 30 years and CEO of 3D Bio-Tissues, BSF’s across Asia, Japan, Australia and wholly-owned subsidiary China § The first to 3D bio-print a human § Commercialised a variety of cornea
Slide 5: Introducing BSF Enterprise
Introducing BSF Enterprise. BSF is a company focused on acquiring biotech companies at the forefront of health and food biotech § Our mission is to unlock the next generation of biotech solutions to transform the delivery of sustainable outcomes § Founded in 2018 and listed on the LSE in 2019 with a
Slide 6: Our Mission
Our Mission. Animal agriculture continues to exacerbate the environmental crisis We need to radically change how protein is produced Tissue engineering can address challenges in carbon reduction by replacing organic tissue with lab-grown equivalents Our mission is to unlock the next generation of bi
Slide 7: Biotech that addresses real challenges
Biotech that addresses real challenges. Tissue engineering that replaces animal tissue with lab- grown scaffold-free bio-equivalents such as: Protein Chicken Beef Pork § Muscle (cultured meat) § Skin (lab grown leather) § Corneas (medical device) Impact on Livestock agriculture is currently responsi
Slide 8: Our growth strategy
Our growth strategy. Our growth strategy is founded on three pillars: Acquire Commercialise Develop Biotechnology Cell Culture Cell Biology & Bioengineering & Tissue Culture & Physiology ■ First acquisition of 3D Bio-Tissues made on IPO in early 2022 ■ Current focus is on developing and commercialis
Slide 9: World leading scaffold-free tissue engineering solutions
World leading scaffold-free tissue engineering solutions. www.3dbiotissues.com
Slide 10: Our journey
Our journey. 15 years of academic Company spun out from IP and development of First 100% lab grown meat study funded by about Newcastle University City-MixTM developed £5M UK funding 2018 Ideas and research into a Focus on meat and Commercial sale of City- new form of tissue Moved to The Bio-sphere,
Slide 11: A platform process
A platform process. ENGINEERED BY FINE-TUNED NANO-STRUCTURE CITY-MIX™ LAB GROWN TISSUES – BIOLOGY PRODUCED BY CELLS “CELL BOOSTER” 100% NATURAL, SCAFFOLD-FREE | 11 © 2023 BSF Enterprise PLC. All rights reserved.
Slide 12: What is Scaffold-Free?
What is Scaffold-Free? § Cultured meat or leather products require structure as well as cells to give the tissue function (texture, mouth-feel, strength) § Structure has previously been generated using synthetic or plant-based scaffolds which do not result in a natural feeling end-product § Our pate
Slide 13: City-Mix Supplements – An Effective Cell Booster
City-Mix™ Supplements – An Effective “Cell Booster”. § Patented non-toxic formulation (zero toxicity) § Inert, food-safe, chemically-defined § Facilitates macromolecular crowding in culture, which: § Creates pockets of higher concentration of soluble growth factors § Improves enzyme kinetics § Provi
Slide 14: Growing Structured Tissues
Growing Structured Tissues. SKIN CORNEA MEAT | 14 © 2023 BSF Enterprise PLC. All rights reserved.
Slide 15: The UK's First Lab-Grown Steak
The UK’s First Lab-Grown Steak. § On 27 January 2023 3DBT produced the UK’s first lab-gown fillet of 100% meat. Further technical test May 26th 2023 § Porcine cells were cultivated in 3DBT’s patented City- Mix™ to produce a fillet of pork and pork strip § Represents an important scientific breakthro
Slide 16: Commercialisation
Commercialisation. § Immediate strategy is to sell City-Mix™ to other biotech companies seeking to boost cell growth: § Currently produce 200 litres per month of concentrate (equivalent to 5,000 litres of media) CITY-MIX™ SALES § Capacity to double the production rate in the near term § Seek partner
Slide 17: Product Pipeline and Commercialisation Strategy
Product Pipeline and Commercialisation Strategy. 3DBT’s City-MixTM, a B2B License evaluation of TE applications for lab- TE applications for Substitute corneas as a product under evaluation 3DBT’s lipopeptide EtsylTM grown skin and out-licensed cultured meat and out- medical device and out- by >20 c
Slide 18: Progress Highlights
Progress Highlights. § Doubled the size of the team and lab space; appointed a new commercial manager § Engaged with over 70 Cellular Agriculture companies with 26 progressing to business opportunities § New Partnerships with Qkine Ltd, and New Harvest to expedite the creation of affordable cultivat
Slide 19: Upcoming Events/Developments
Upcoming Events/Developments. § Progressing partnerships with established food manufacturers Q4 2023 § Working with Hong Kong office to recruit sales and technical staff § Joint project on development of lab-grown corneas Q4 2023 § Expand City-Mix™ manufacturing and commercial team H1 2024 (EIT Gran
Slide 20: BSF Enterprise PLC (Board of Directors)
BSF Enterprise PLC (Board of Directors). Min Yang Geoffrey Baker Dr. Che Connon Dennis Ow Graham Duncan Chair Director Managing Director Non-Executive Director CFO § A wealth of experience § A qualified lawyer in § The first to 3D bio-print a § Formerly a business § A Chartered Accountant spanning o
Slide 21: Summary
Summary. Investment in BSF provides exposure to the compelling and rapidly growing industrial tissue engineering market IP protection: City-Mix™ media boosts cell growth, whilst tissue templating produces highest quality animal tissue 1 Highly differentiated: City-Mix™ is chemically defined; tissue
Slide 22: Investor Relations Information
Investor Relations Information. ADVISORS Brokerage Shard Capital Brokers UK Legal Ince Lawyers Communications SEC Newgate 3DBT@secnewgate.co.uk. UK Stock Code: LON:BSFA US OTCQB Code: BSFAF:QBB Website: bsfenterprise.com | 22 © 2023 BSF Enterprise PLC. All rights reserved.
Slide 23: BSF Press Coverage (continued)
BSF Press Coverage (continued). | 24 © 2023 BSF Enterprise PLC. All rights reserved.
Slide 24: Industry Press Coverage
Industry Press Coverage. | 25 © 2023 BSF Enterprise PLC. All rights reserved.
Slide 25: Investor Relations - skylineccg.com
Investor Relations - skylineccg.com LON:BSFA (UK) | BSFAF:QBB (US) www.bsfenterprise.com © 2023 BSF Enterprise PLC. All rights reserved.
BSF Enterprise — Investor Presentation (September 2023) on 6ix